Piroxicam: Source for Synthesis of Central Nervous System (CNS) Acting Drugs

Author(s): Saganuwan Alhaji Saganuwan*.

Journal Name: Central Nervous System Agents in Medicinal Chemistry

Volume 17 , Issue 2 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The use of central nervous system (CNS) acting drugs in the management of neuro degenerative and psychiatric problems cannot be overemphasized. Therefore, the chemical structure of piroxicam can be modified to yield new CNS stimulants and depressants that can be of great benefit to man and animals.

Methodology: Acetylcholine has Methyl - Oxygen-Oxygen (M-O-O) and Nitrogen (N) functional groups which are structurally related to Sulphur-Oxygen-Oxygen (S-O-O) and Nitrogen (N) of piroxicam that are either methylated or hydrogenated. Each arecoline and nicotine has M-O-O in addition to methylated nitrogen and pyridine ring respectively, making them structurally related to piroxicam. Therefore, when Sulphur of piroxicam is replaced by methyl group, it may likely have muscarinic effects expressed by glandular secretion, gut sedation and vasodepression. Whereas the nitrogen group may be responsible for cholinergic effect in gaglia and striated muscle. Because of the carboxylic functional group (COOH), piroxicam may display depressant effect. Hence C = O, C = N and C = C in piroxicam may change due to biofield treatement.

Conclusion: The conversion of piroxicam to central nervous system (CNS) acting drugs may be by desulphation, methylation, dehydrogenation, carboxylation and carbonylation. The would-be synthesized CNS drugs from piroxicam, should have low molecular weight, lipid solubility and low PH.

Keywords: Blood-brain-barrier, CNS, depressant, pharmaceutics, piroxicam, stimulant.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 2
Year: 2017
Page: [135 - 140]
Pages: 6
DOI: 10.2174/1871524916666160719102335
Price: $58

Article Metrics

PDF: 25
HTML: 1
EPUB: 1
PRC: 1